Chardan Capital restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report published on Thursday, January 30th, TipRanks reports.

A number of other analysts have also recently commented on CRSP. Piper Jaffray Companies reiterated a buy rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 16th. Canaccord Genuity upped their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. BidaskClub lowered Crispr Therapeutics from a hold rating to a sell rating in a research note on Thursday, January 23rd. Oppenheimer upped their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research report on Monday, November 25th. Finally, Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of Buy and a consensus target price of $75.95.

Crispr Therapeutics stock opened at $52.32 on Thursday. The stock has a market cap of $2.89 billion, a PE ratio of -113.74 and a beta of 3.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a one year low of $29.92 and a one year high of $74.00. The stock has a fifty day moving average of $59.31 and a 200 day moving average of $52.83.

In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at approximately $465,000. The disclosure for this sale can be found here. Insiders sold a total of 48,618 shares of company stock valued at $3,230,760 in the last three months. Insiders own 21.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after purchasing an additional 343 shares in the last quarter. Traynor Capital Management Inc. raised its holdings in Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after purchasing an additional 375 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after purchasing an additional 386 shares in the last quarter. Advisory Services Network LLC raised its holdings in Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock worth $41,000 after purchasing an additional 400 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Crispr Therapeutics during the 4th quarter valued at approximately $26,000. 50.01% of the stock is owned by hedge funds and other institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Understanding the different types of bonds

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link